Keyword: Frank D'Amelio

Pfizer moved rheumatoid arthritis patients to a lower Xeljanz dose after a data monitoring board highlighted safety concerns for the 10-mg arm.

Some new CEOs fill out their executive team roster over time as leaders from the previous regime make their exits. Not Pfizer’s.

Pfizer CEO Ian Read contends that the company's pipeline is strong enough to fuel growth. In other words, don't look for a "transformative" deal.

Pfizer’s finally getting what it always wanted in U.S. tax reform. And now, all eyes are on what it will do next.

With an impending drop in the corporate tax rate, Pfizer is providing a preview of what Big Pharma's priorities are likely to be.

As usual, Pfizer’s hot-shot breast cancer med Ibrance posted strong numbers in the fourth quarter, but that wasn't enough to bail Pfizer out on the earnings front.

If you’ve watched Pfizer’s recent dealmaking, you've noticed a trend: It likes buys that bring in new revenue, and quickly. That's a pattern the company intends to stick with.